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ABSTRACT
Background: At the concept stage, many uncertainties surround the com-
mercial viability of a new medical device. These include the ultimate
functionality of the device, the cost of producing it and whether, and at
what price, it can be sold to a health-care provider (HCP). Simple assess-
ments of value can be made by estimating such unknowns, but the levels
of uncertainty may mean that their operational value for investment
decisions is unclear. However, many decisions taken at the concept stage
are reversible and will be reconsidered later before the product is brought
to market. This ﬂexibility can be exploited to enhance early-stage
valuations.
Objectives: To develop a framework for valuing a new medical device at the
concept stage that balances beneﬁt to the HCP against commercial costs.
This is done within a simpliﬁed stage-gated model of the development cycle
for new products. The approach is intended to complement existing pro-
posals for the evaluation of the commercial headroom available to new
medical products.
Conclusions: A model based on two decision gates can lead to lower
bounds (underestimates) for product value that can serve to support a
decision to develop the product. Quantiﬁable uncertainty that can be
resolved before the device is brought to market will generally enhance
early-stage valuations of the device, and this remains true even when some
components of uncertainty cannot be fully described. Clinical trials and
other evidence-gathering activities undertaken as part of the development
process can contribute to early-stage estimates of value.
Keywords: cost–utility analysis, headroom method, investment under
uncertainty, medical devices, value-based pricing.
Section 1—Introduction
Manufacturers and vendors bringing new health-care technolo-
gies to market are increasingly required to demonstrate value for
money. For instance, the National Institute for Health and Clini-
cal Excellence in the UK has developed formal methods of eco-
nomic evaluation that explicitly set funding norms, one effect of
which is to moderate acceptable prices for drugs and devices.
Meanwhile, from a vendor’s perspective, this changing terrain
will affect the choice of product to invest in and the level of
investment that is warranted, given the price a particular product
may attract in the marketplace. This places considerable pressure
upon early-stage decisions. Nevertheless, much of the long-term
impact of a given device will be shaped by such decisions, which
are often made quickly and with limited evidence.
Several studies have drawn attention to the increasing use of
early-stage economic models for medical products while
acknowledging the uncertainties inherent in such a modeling
enterprise [1,2]. Some proposals envisage ongoing health-
economic assessment as an integral part of the development cycle
[3–5]. In two recent articles, a method was presented for scoping
the gross commercial opportunity (or “headroom”) by establish-
ing a simple price ceiling available to a manufacturer based on an
estimate of clinical effectiveness within a cost–utility model [6,7].
The aim of this work was to provide a quick method for rapid
decision-making that would support, for instance, the selection
of promising concepts from a larger pool of options. It throws a
helpful focus on the most important performance aspects of the
device in question and facilitates a rational discussion to support
a go/no-go investment decision. Nevertheless, it disregards the
uncertainty that will be present at the start of a new product
development cycle, focusing instead on plausible expectations
within an optimistic scenario for the performance of a new
device.
In this article, we seek to extend the method to incorporate
some allowance for uncertainty into the early-stage assessment
process. This is done by introducing a downstream decision gate
into the development cycle for the new device at which produc-
tion and marketing decisions will be taken. In general the addi-
tional ﬂexibility offered by the later gate can only increase the
early-stage value as derived from a naive headroom approach [8].
This is key to understanding why it may be rational for a com-
mercial organization to disregard an unfavorable assessment
conducted at an early stage in the development of a new product.
The extent of the increase in value is sensitive to the amount of
information that will accrue (or uncertainty that will be resolved)
during the development cycle. Nevertheless, the approach out-
lined here does not rely on having a comprehensive model for the
evolution of the information base; it can be exploited to obtain a
lower bound (underestimate) for early-stage value whenever a
resolvable uncertainty is identiﬁed and thus tends to support
decisions to invest in new products whose potential looks mar-
ginal at the start. A further beneﬁt of this analysis is to focus on
some critical issues that lie at the heart of successful product
development. Speciﬁcally, it connects uncertainty over evidence
with operational risk management and provides a way of inform-
ing business review processes.
This situation facing a manufacturer at the start of the
product development cycle is not dissimilar to that faced by a
health-care provider (HCP) encountering a fully-ﬂedged technol-
ogy with an inconclusive cost-effectiveness analysis. For the HCP,
a key theoretical role is played by value-of-information analysis,
which aims to determine whether the possible beneﬁts of the
technology can justify a decision to collect further information,
usually in the form of a clinical trial [9–12]. The approach is
fundamentally Bayesian and will often use empirical data from
small trials to construct the necessary prior distribution for the
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net beneﬁt of the technology [13]. Sometimes the lack of sufﬁ-
cient empirical data means that the only option is to use expert
judgment when constructing the prior [14,15]. Similarly, the
implementation of our proposals will often rely on expert judg-
ment to characterize uncertainty in the early stages of product
development where empirical evidence is necessarily limited [16].
The article is structured as follows. Section 2 describes the
early-stage valuation model using illustrations based on uncer-
tain production costs—whose value can be expected to be fully
resolved before the decision to market is made. In section 3
health-economic uncertainties are introduced into the mix and
the role of different approaches to product-pricing is discussed.
Section 4 contains a brief discussion of the applications and
limitations of the approach.
Section 2—Early-StageValuation withTwo
Decision Gates
Our approach to commercial project valuation is based on the
net present value of future cash ﬂows [16]. For decision-making
purposes, future costs and revenues will be discounted using an
internal rate of return, consistent with company policy that is
supposed to reﬂect the inherent riskiness of the product portfolio
to which the device belongs. Throughout this article, we assume
that this discounting has already taken place, and the term “cash
ﬂow” is taken to denote “cash-ﬂow discounted to a (speciﬁed)
time-point.” Furthermore, it is assumed that there is a deﬁnite
time horizon over which postmarket cash ﬂows (PMCF) contrib-
ute to the early-stage assessment of product value. In principle,
the horizon will not be the same for all products. Our discussion
applies to a period of time over which the new device can
command a ﬁxed price chosen to reﬂect its contribution to health
care. Rationally, this will last until either the treatment associated
with the device is superseded or other companies enter the
market with competing products. In practice, the postmarket
planning horizon may be ﬁxed by company policy. In any event
the expectation will be that development costs should be
recouped over that period.
With these provisos, the decision to proceed with the devel-
opment of a product concept into a concrete medical device will
be justiﬁed if the anticipated PMCF from the device exceed the
costs of development. In practice, a decision to develop a new
product will be reviewed at later stages of the development cycle,
and certainly in the immediate premarket phase, to see if the
outlook for the product remains favorable. Here we consider a
simpliﬁed model of a commercial development cycle for a new
device that consists of three phases separated by two decision
gates (Fig. 1).
The ﬁrst phase (P1) produces an initial idea followed by some
form of feasibility study before the product can be presented as a
candidate for further development. At G1 a decision is taken
whether to enter a full development phase (P2). At the end of the
development phase a ﬁnal decision is made to bring the product
to market. At this point (G2) the product will enter the postmar-
ket phase (P3) with the corresponding commitment to the costs
of production and the development of a pricing and marketing
strategy, or else the project will be abandoned altogether. In
practice, the project may be subject to interim reviews that might
be modeled using additional decision gates. But such additional
gates can only enhance the value of the product idea as initially
perceived [17], so that our two-gate model will lead to a lower
bound on early-stage value.
The analysis of a stage-gated development model requires
that the initial uncertainty about commercial performance be
partitioned into different components depending on the point in
the development cycle at which the uncertainty will be resolved.
For our model this is a partition between developmental uncer-
tainties (i.e., resolved during P2) and postmarket uncertainties
(resolved during P3).
Developmental Uncertainty
Developmental uncertainty refers to those aspects of the product
design and performance that will be resolved during the devel-
opment phase (P2). These will necessarily include details of
design and manufacture, with precise requirements for plant,
labor, and raw materials; speciﬁcation of the performance of the
product—i.e., whether, and to what extent, the new device can
achieve the anticipated technological performance. During the
developmental phase, it may also be possible to ﬁrm up some of
the early assessments of the health beneﬁts and treatment costs
associated with the device and to use this additional information
to update a health-economic model of the associated therapy.
Postmarket Uncertainty
Postmarket uncertainty encompasses those aspects of commer-
cial performance that will not be resolved in time to inﬂuence the
decision to launch the product into the marketplace. The most
obvious component here is the volume of sales that will be
achieved and, perhaps, the price at which sales can be made. For
medical devices, the major part of this uncertainty may be propa-
gated through future purchasing decisions of HCPs. If these
involve reimbursement/coverage decisions, purchase volumes
may be partly predictable from the perceived health-economic
performance of the device and thus tied in with some issues that
are resolved at the developmental stage. Nevertheless, there will
often be substantial error bounds on predicted sales for a product
brought to market, an indication that the uncertainty will not be
resolved until after it is too late to inﬂuence the marketing
decision. Production costs are less likely to wait on a market
response before their value is known: the price of labor is
unlikely to vary much over the planning horizon, and small
increases can be budgeted for; the cost of capital items will be a
“given” by the time the items are required; futures markets can
be used to stabilize raw material costs. Perhaps the major source
of cost uncertainty that remains relates to the size of the market
because this will impact on the availability of economies of scale.
Estimating Product Value
The development cycle is driven by the expectation that the
PMCF generated in P3 will be sufﬁcient to justify the develop-
ment of the product. At the market decision gate, G2, the project
will be abandoned if it is anticipated that future cash ﬂows will
be unfavorable to the company. In other words, the “value” of
the product to the company at G2—denoted by V2—is equal toFigure 1 A development cycle with two decision gates.
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the predicted PMCF—unless this is negative, in which case it is
zero. In mathematical terms this is
V Y2 0= ( )max ,
where Y is the estimate of PMCF available at G2, which will
(necessarily) be averaged over postmarket uncertainties. This
valuation is represented by the solid line in Figure 2.
At G1, the investment decision gate, the company must
balance the costs of the development phase (as estimated at G1)
against a prediction for V2 that takes account of the fact that the
outlook for PMCF is likely to change over the course of the
development cycle. The early-stage prediction for V2 is obtained
by averaging V2 over the developmental uncertainties to obtain
V YY1 0= ( )E max , .
This is the value (at G1) of the PMCF associated with the
product taking account of the ﬂexibility offered by the later
decision gate G2 and is represented by the broken line in
Figure 2. It (i.e., V1) is necessarily greater than max(EYY, 0),
which is the point on the solid line corresponding to the early-
stage estimate of PMCF (EYY) that ignores the later decision
ﬂexibility. In other words, the early-stage valuation of postmar-
ket performance will always exceed the late-stage valuation
based on the same cash-ﬂow estimate. Development costs can
now be put into the equation; in principle, the product should go
into the development phase if these are outweighed by the early-
stage valuation of PMCF. The criterion is to proceed to phase 2
provided that
V1 Expected cost of development> .
If this criterion is satisﬁed, the early-stage valuation is V1
minus the expected development costs; if not, the product idea
has no value (at least within the limitations of this model.)
A key point for this approach is that some of the uncertainty
about phase 3 cash ﬂows that is present at G1 will have been
resolved by G2. This feature generates a more favorable outlook
for the project at G1 than indicated by a straightforward cash-
ﬂow projection and can sometimes justify the development of a
product that does not currently promise a commercial proﬁt.
For a simple example, suppose that both sales and production
costs are subject to predictive uncertainty but that the costs are
uncertain only to the extent that the details of the product design
have yet to be ﬁnalized. The development phase (P2) is supposed
to uncover the true production costs but shed no new light on
sales revenue. The PMCF can be expressed as
PMCF Sales Revenue Costs= −
At G1 the outlook for Costs is represented by a Normal
distribution with mean £100 and speciﬁed SD. The implied early-
stage valuation (V1) of the PMCF, as a function of predicted
Sales, is plotted in Figure 3, for several different levels of cost
uncertainty (see Appendix A2 for details at http://www.ispor.org/
Publications/value/ViHsupplementary/ViH13i5_Girling.asp). It
is evident that the capacity of the development phase to resolve
the cost uncertainty can lead, in this hypothetical example, to a
substantial enhancement of perceived product value and may
well justify a decision to develop the product even when the
predicted PMCF is close to zero or even negative. For example, if
Sales are predicted at £100 (implying a predicted net cash ﬂow of
zero), the early-stage value (net of development costs) is about
40% of the SD.
Partial Allowance for Developmental Uncertainty
The early-stage valuation of PMCF proposed above depends on
classifying all the components of cash-ﬂow uncertainty into one
of two types—what we have termed “developmental” and “post-
market” uncertainties. In particular, we need to know in advance
exactly what questions will be resolved during the development
cycle. In practice, this may be an unrealistic requirement. The
development process may take months or years, during which
time any number of unexpected things may happen: a clinical
trial or health-economic study may report which settles the value
of an important parameter in the cost-effectiveness analysis; a
competitor product may enter the market with serious effects on
likely sales; extra productive capacity may become available as a
result of an internal company reorganization, or by acquisition.
A whole host of eventualities may bear on the outlook for the
product, and it is not realistic to assess every one of these in
advance.
Fortunately it is not always necessary to do so. A lower
bound on early-stage product value can be generated with respect
to any selection of developmental uncertainties—provided only
that these will deﬁnitely be resolved by the time the marketing
Figure 2 Schematic valuation of postmarket cash ﬂows: (a) at G2, the market
decision gate (solid line); (b) at G1, the investment decision gate (broken line)
showing the value of future ﬂexibility at G2.
Figure 3 Early valuation of postmarket cash ﬂows with predicted production/
marketing costs of £100 as a function of predicted sales. Five levels of cost
uncertainty are illustrated.The broken lines represent SDs of £20, £30, £40, and
£50.Value increases with SD. The solid line corresponds to zero cost uncer-
tainty (i.e., SD = 0).
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decision has to be taken. For example, they might encompass the
results of a planned clinical trial together with a complete speci-
ﬁcation of production costs but will not include the full range of
relevant issues that will be resolved before the marketing decision
can be taken. It is shown in Appendix A1 at http://www.ispor.
org/Publications/value/ViHsupplementary/ViH13i5_Girling.asp
that a partial valuation based on a subset of the developmental
uncertainty is guaranteed to underestimate the full early-stage
valuation V1. In many circumstances a partial valuation will be
sufﬁcient to support a decision to develop the product if it is
found to outweigh the cost of the development phase.
Suppose, in the previous example, that the sales outlook was
liable to change during the development period. Then the valu-
ation given in Figure 3 for a particular level of predicted sales
would constitute a partial valuation and would furnish an under-
estimate of the value of the product idea to the company. For this
argument to hold it is necessary only that the predicted sales
ﬁgure encapsulates an unbiased estimate of what the actual sales
will be at the time the valuation is made. Nevertheless, a devel-
opment decision that was supported when the sales outlook was
not liable to change would still be supported in the new situation.
Valuation with a Standard Model for PMCF
More realistic is a standard cash-ﬂow model that takes account
of a ﬁxed/variable cost structure:
PMCF = × − − ×N P F N L,
where N is the number sold, P is the unit price, F is the ﬁxed
(production/marketing) cost, and L is the variable (production/
marketing) unit cost. Such a model is implicitly assumed for the
remainder of this article. Here we use it to illustrate the impact of
resolvable cost uncertainty on early-stage valuation. At the early
decision gate, G1, suppose that the ﬁxed cost F is predicted as
£50,000 and the variable cost L as £250 per item, but these
values are uncertain and will be known precisely only at the end
of the development phase. The uncertainty in the cost compo-
nents is modeled by means of two independent log-normal dis-
tributions, with the same coefﬁcient of variation (CV). A selling
price of £1000 per item is assumed.
At this price, the PMCF are predicted to break even when 67
items are sold because the sales revenue of £67,000 is then
balanced by the estimated ﬁxed cost (£50,000) + 67 ¥ the esti-
mated variable cost (£250). Figure 4 represents the partial early-
stage valuation as a function of sales, assuming a predetermined
selling price but allowing for different levels of developmental
cost uncertainty. Once again developmental uncertainty has sub-
stantially enhanced early-stage value. This is certainly true at
sales volumes close to the predicted break-even point (i.e., 67).
Moreover, the effect does not disappear at higher volumes (unlike
the situation depicted in Figure 3 where the broken lines con-
verge on the solid line at high sales levels) essentially because the
production costs now include a component that is proportional
to sales volume.
Section 3—The Role of Economic Assessments
Cost uncertainty is only part of the valuation problem because
future cash ﬂows will depend critically on the success of a pricing
and marketing strategy. For many medical devices, sales will rely
heavily on the purchasing behavior of one or more large HCPs.
Inevitably, such organizations will need to weigh the health value
of the product to its subscribers against its costs, which will
include the price of the device together with any additional costs
of the treatment associated with its use. In some cases the new
device might even promise a reduction in the costs of care—a
powerful support to any sales campaign. Thus, although pur-
chasing decisions can be, and often are, made without reference
to the formal methods of health economics, these provide a
convenient paradigm for thinking about purchasing behavior.
Moreover, where an HCP does engage in reimbursement/
coverage processes for clinical treatments, the conclusions are
often informed by economic analyses. In this context cost–utility
modeling based on a stated (or implied) threshold for the value of
a quality-adjusted life-year (QALY) often takes a leading role,
especially in the UK [18,19]. Given the importance of such
models for understanding the attitude of HCPs to existing
medical products, it is natural to ask how economic models
constructed at an early stage of the development cycle can con-
tribute to a realistic commercial valuation of a new device
concept.
A standard paradigm for health technology assessment uses
an incremental cost-effectiveness ratio (ICER) of the form
Δ ΔC Q
where DC and DQ represent the incremental treatment costs
(measured in £s) and health beneﬁts (measured in terms of
QALYs) per patient compared with current treatment practice
[20]. We assume throughout that all costs and QALYs have been
discounted at an appropriate rate (currently 3.5% p.a. for both
costs and beneﬁts to the National Health Service [NHS] in
England). A technology will be favorably assessed if the ICER is
less than a declared threshold l (£20,000—£30,000 for the
NHS). Inevitably, the price of the device will ﬁgure in the com-
putation of DC. Thus, the cost–utility paradigm establishes a
maximum price at which the device can be reimbursed. One
possibility for the manufacturer is to set the price at this
maximum level, where it will generate the greatest possible
revenue without (apparently) jeopardizing the chances of a favor-
able purchasing decision. This is the principal of value-based
pricing [21]. Value-based pricing is possible only if the price is set
at a very late stage—when the HCP’s assessment of the economic
value of the device is fully developed. In practice, this may be
feasible only when price negotiation is undertaken as part of the
procurement process. In terms of the development cycle model,
Figure 4 Early valuation of postmarket cash ﬂows with ﬁxed and variable
production cost uncertainty as a function of predicted sales. Five levels of cost
uncertainty are illustrated.The broken lines represent coefﬁcients of variation
(CVs) of 0.3, 0.5, 0.7, and 1.Value increases with CV.The solid line corresponds
to zero cost uncertainty (i.e., CV = 0).
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this could mean that the price is ﬁxed at the G2 decision gate in
accordance with the purchaser’s valuation and that the sales are
then guaranteed. Or it could mean that the value-based price
(VBP) will emerge from downstream negotiations after the G2
decision has been taken. For early-stage valuation it is immaterial
which of these possibilities will be realized; both can be handled
within the same analytical framework.
Under cost–utility analysis, the VBP is
VBP = − ′λΔ ΔQ C
where DC′ denotes the component of incremental health-care
costs that excludes the price of the device and DQ is the incre-
mental QALY gain, as usual. At the very early stages of devel-
opment of a novel device, relevant empirical data will be limited
and might even be conﬁned to some aspects of health service
costs collected for treatments with similar clinical requirements
(e.g., length and complexity of surgical procedure.) Thus, the
cost–utility model may be partly speculative and will almost
certainly rely on expert opinion to quantify the uncertainties
involved. Its commercial function may be seen as that of provid-
ing an initial assessment of the likely value of VBP, in the form of
a posterior probability distribution that combines prior opinion
(especially about effectiveness) with such empirical data as might
already be available. Later in the development cycle more infor-
mation will be available and the posterior distribution for VBP
will be updated.
Early-Stage Valuation under Value-Based Pricing
Under value-based pricing, it is assumed that the volume of sales
(N) is not affected by the actual level of the price: once the VBP
has been ﬁxed, the market size will be determined solely by the
epidemiology of relevant clinical conditions within the health-
care system. This is consistent with the notion that the cost–
utility analysis fully captures the value of the device to the HCP.
Further, we assume that the marketing and production costs
associated with these sales are given by
F N L+ ×
where both the ﬁxed (F) and variable (L) cost components are
known at G2, when the decision to market has to be made. The
projected PMCF at G2 are given by
Y N F N L= × − − ×VBP2
where VBP2 denotes the predicted value of VBP as perceived at
the G2 decision gate. (Mathematically this means that
VBP2 = E(VBP|G2), a conditional expectation given what is
known at G2.) Alternatively we could write




L= + denotes the unit cost, apportioned equally
between all N sales. Early-stage valuation of the PMCF must take
account of the predictive uncertainty about VBP2 that is present
at G1. In some circumstances the health-economic uncertainty
will be largely resolved during the development phase. Then
VBP2 and VBP will coincide and the posterior distribution for
VBP derived from an economic assessment can be used in the
early-stage valuation. In other cases, the health-economic infor-
mation base will still be incomplete at G2. In these cases the
posterior distribution for VBP will be too diffuse for the purpose
of early-stage valuation. It is necessary, in these cases, to assess
the degree to which the uncertainty about VBP is likely to be
resolved during the development phase. In practice an estimate of
the resolvable uncertainty can always be obtained if the manu-
facturer decides to sponsor a trial of the device as part of the
development process. Indeed, such a trial may be designed with
the aim of achieving a speciﬁc degree of precision for the estimate
of VBP, which will feed through into a lower bound for the
early-stage value. The calculations are similar in principle to
those associated with sample information methods for designing
clinical trials from a public perspective [9,11].
An example: early valuation of a tissue-engineered (TE) bladder.
McAteer et al. [7] discuss the viability of a TE substitute for
cystoplasty in carcinoma of the bladder. Their approach relies on
optimistic assumptions for the performance of the technology to
derive maximum headroom for its commercial prospects. The
health beneﬁt turns on avoiding the disutility (D) associated with
the complications of conventional cystoplasty. In addition, a
potential saving of 4 hospital days per patient, at £317 per day,
was identiﬁed. Their calculation assumes a cost-effectiveness
threshold of £30,000 per QALY, with the beneﬁts extending over
an (undiscounted) average patient life-expectancy of 10 years.
This leads to headroom of
£30,000 10 D £317× × + ×4 .
(Here the effect of discounting at 3.5% would be to replace the
factor 10 with 8.56 in the ﬁrst term of this expression.) A point
estimate of the disutility D (= 0.05) obtained from a sample of
four urologists was used, but no opinion on the precision of the
estimate was elicited. The authors conclude that the total head-
room stands at £16,268 (or £14,113 with discounting) consid-
ered to offer good prospects for a commercially viable price
because unit costs (including development costs) are unlikely to
exceed this value.
Properly, the disutility of cystoplasty should be obtained from
a public or patient population study using a preference method
[22]. The urologists’ estimate (0.05) is perhaps best regarded as
a prediction for the result of such a study, whose outcome is
currently uncertain. Here we model the uncertain outcome of the
study using beta distributions [23] for the disutility, with mean
0.05 and CVs chosen to reﬂect different levels of prior uncer-
tainty. The curves in Figure 5 show early-stage valuations on the
assumption that all uncertainty about the disutility will have
been resolved before the decision to market is taken. (In practice,
Figure 5 Commercial value of postmarket cash ﬂows for a tissue-engineered
bladder as a function of unit cost of production, with allowance for uncertain
disutility of cystoplasty. Five levels of uncertainty are illustrated. The broken
lines represent coefﬁcients of variation (CVs) of 0.2, 0.5, 0.8, and 1.0. Value
increases with CV.The solid line corresponds to a certain disutility of 0.05 and
supports the headroom analysis of McAteer et al. [7].
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this may be unrealistic, but an approximate valuation can be
obtained from these curves if the CV is down-weighted by a
factor that reﬂects the size of the sample in the new study. The
calculations will vary with the details of the individual case and
are not reproduced here. In examples with very imprecise priors,
the down-weighting will have little effect.) The valuation is
shown as a function of the postmarket unit costs, which will
most likely become known during the development phase and are
in any case independent of the health-economic analysis.
The chosen values of CV correspond to different upper
97.5% prediction limits for D, as follows: CV = 0.2, 0.5, 0.8 1.0;
upper limit = 0.07, 0.11, 0.15, 0.18. For example, if there is a
non-negligible chance that the population disutility will turn out
to be greater than 0.10, a realistic valuation should allow for a
CV of at least 0.5. This would lead to a substantial enhancement
of early-stage value, especially if the naïve prediction of PMCF
leaves little room for proﬁt. Taking CV = 0.5 gives an early-stage
commercial valuation of £2,900 per patient even when the best
estimate of commercial headroom (£16,268) is exactly balanced
by the projected unit costs. This paradoxical result relies on the
ﬂexibility to abandon the product once the disutility is fully
determined. Thus, a promising strategy might be to elicit the
disutility of cystoplasty in a population study before embarking
on the product development phase. This has the potential to
further enhance value by avoiding the costs of development
should the elicitation prove unfavorable.
In this example, uncertainties about production/marketing
costs and sales volume have been ignored. The effect of having
done so will most likely lead to a diminished early-stage valua-
tion because Y, the PMCF estimate at G2, is linear in both costs
and sales volume. Applying the result in Appendix A1 at http://
www.ispor.org/Publications/value/ViHsupplementary/ViH13i5_
Girling.asp, this means that the early-stage valuation is reduced
when these quantities are replaced by their expected values. Full
valuation could be obtained by averaging the appropriate curve
in Figure 5 over a realistic probability distribution for unit costs,
and this is guaranteed to exceed the valuation using expected
costs.
Alternative Pricing Models
The value-based pricing model is a straightforward way of incor-
porating cost–utility analysis into commercial product valuation
for medical devices. Essentially it assumes that the manufacturer
will enjoy the full societal value of the new technology by selling
at a price that is at the extreme limit for a cost-effective technol-
ogy. Yet in the real world of the medical devices market this may
be neither a feasible nor a sensible aspiration. Often a guide price
must be declared in advance of any sales negotiations. In such
cases the price level can inﬂuence the decision of an HCP whether
or not to purchase the device at all, and must be set with this in
mind. It is clearly dangerous to attempt to achieve the full VBP in
these circumstances because this would be accompanied by a
signiﬁcant risk that the product will be declined. Theoretically
the risk is close to 50% because it is a toss-up for the HCP
whether to fund a treatment on the boundary of cost-
effectiveness. Indeed, it could be argued that true value-based
pricing is achievable only under special institutional arrange-
ments, such as those that have been proposed for pharmaceutical
products in the NHS [21].
In the absence of formal endorsement for VBP from the HCP,
a company must balance the risk of failure to sell at all against
the danger of selling too cheaply. One approach is to set the price
as a weighted average of the estimated VBP and the unit cost of
production. Weights in the ratio of about 5 to 1 have been
suggested (Girling AJ, Lilford RJ, Young TP, unpublished data)
based on a proﬁt-maximizing criterion.
This has a knock-on effect on early-stage valuations, reducing
them by around 17% compared with a VBP regime, with a
further reduction equal to 17% of the attributable ﬁxed costs.
Even with these adjustments the question remains whether the
HCP can be persuaded to purchase the device at the stated price,
an issue that does not arise under VBP. The attitude of the HCP
will depend on a number of factors, including the possibility that
new data will cause a revision of the cost-effectiveness outlook
before the purchasing decision is taken, budgetary constraints on
the purchasing arm of the HCP, the effectiveness of the marketing
campaign, and the intervention of competing products or treat-
ments. Some of these factors can be modeled, but the ultimate
goal of any marketing campaign is a successful human interac-
tion at the point of sale, and this must depend on the particu-
larities of the parties involved. Thus, a further deﬂation of
early-stage value is necessary: in principle all components of
value that depend on the volume of sales should be multiplied by
an estimate of the probability (necessarily less than 1) that the
sales negotiations can be brought to a successful conclusion at
the nominated price. Further work could be undertaken to model
this complex situation.
Discussion
We have conceptualized early product valuation in terms of an
investment decision, exploiting the ﬂexibility offered by decision
gates later in the development cycle. The early-stage value of the
PMCF is the maximum that could rationally be invested in the
development process. We have avoided the complexities of a full
investment analysis based on the options approach [24–26] and
focused instead on a simple model with just two decision gates.
Additional gates can only increase value. Thus, our approach
generates lower bounds (underestimates) for product value. Simi-
larly, lower bounds are generated when partial allowance for
uncertainty is made. Often these will be sufﬁcient to support an
investment decision. If not, it is possible that increased valuations
may follow from a more complete analysis of the uncertainties
involved.
When making early-stage valuations, it seems that value is
enhanced when the outlook is uncertain—uncertain cash ﬂows
appear to be more valuable than certain cash ﬂows. This para-
doxical state of affairs arises because of the ﬂexibility offered
by subsequent decision gates. It does not amount to risk pref-
erence; nor is it an invitation to willfully overstate the degree of
uncertainty involved. Uncertainty is advantageous only in a
certain sense. The expected value of any information that
would resolve some part of the developmental uncertainty is
necessarily positive. Indeed, there is a strong connection
between the current work and value-of-information analysis.
There is, however, a conceptual difference: value-of-information
analysis is usually predicated on a decision scenario in which
any one of two or more options can be pursued even if no
additional information is collected. In the commercial situation
the option to proceed with the product while bypassing the
development phase is not available because the development
phase is essential for the realization of a product concept. Thus,
it is not the value of the development information that should
inform the investment decision but the full early valuation of
the product.
The usefulness of this approach hinges on an understanding of
the process of information accrual during the development phase.
The available information concerning the performance of a device
that has yet to be built is likely to accrue rapidly during the
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development phase. For the ﬁrst time, it becomes possible to
collect empirical data from bench tests and clinical trials. Given a
signiﬁcant degree of prior ignorance about product performance,
the information content of the ﬁrst few empirical observations will
often be very high, and certainly higher than can be expected from
the same number of observations taken later. Thus, a trial planned
as part of the development phase can be expected to deliver good
value for money and can, by itself, support a partial valuation that
gives a lower bound on the early-stage value. For a full early
valuation it is necessary to foresee the extent of all the
information-gathering processes that will take place, including
those outside the domain of any individual company. Sometimes
the modeling assumptions themselves will change over the devel-
opment phase: for instance, a case based on health-economic
considerations can be undermined if existing therapies improve,
leaving less headroom for the new device. Such possibilities may
not be foreseeable in advance. They contribute to the overall
riskiness of the medical device sector.
A key application arises when a critical uncertainty about
product performance or cost can be identiﬁed, on which the
ultimate viability of the device will depend. In such a case it is
worthwhile to acquire a comprehensive understanding of the
critical issue before proceeding with the development phase. A
partial valuation (as described in section 2.2) that allows for the
developmental uncertainty around the critical issue will not over-
state the rational value of the product and can safely be used to
underpin an investment decision.
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